2021
Twelve-Month Retention in Opioid Agonist Treatment for Opioid Use Disorder Among Patients With and Without HIV
Wyse JJ, McGinnis KA, Edelman EJ, Gordon AJ, Manhapra A, Fiellin DA, Moore BA, Korthuis PT, Kennedy AJ, Oldfield BJ, Gaither JR, Gordon KS, Skanderson M, Barry DT, Bryant K, Crystal S, Justice AC, Kraemer KL. Twelve-Month Retention in Opioid Agonist Treatment for Opioid Use Disorder Among Patients With and Without HIV. AIDS And Behavior 2021, 26: 975-985. PMID: 34495424, PMCID: PMC8840957, DOI: 10.1007/s10461-021-03452-0.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidCohort StudiesHIV InfectionsHumansMethadoneOpiate Substitution TreatmentOpioid-Related DisordersConceptsOpioid agonist therapyOpioid use disorderVeterans Aging Cohort StudyHIV statusUse disordersOpioid agonist treatmentAging Cohort StudyDiagnosis of HCVTwelve-month retentionPositive health outcomesOAT retentionAgonist therapyCohort studyHIV managementAgonist treatmentPredictors of retentionPatientsHealth outcomesHistory of homelessnessHIVLower likelihoodImproved likelihoodLikelihood of initiationBuprenorphineDisorders
2020
Trajectories of Self-Reported Opioid Use Among Patients With HIV Engaged in Care: Results From a National Cohort Study.
Edelman EJ, Li Y, Barry D, Brennan Braden J, Crystal S, Kerns RD, Gaither JR, Gordon KS, Manhapra A, Merlin JS, Moore BA, Oldfield BJ, Park LS, Rentsch CT, Skanderson M, Williams EC, Justice AC, Tate JP, Becker WC, Marshall BDL. Trajectories of Self-Reported Opioid Use Among Patients With HIV Engaged in Care: Results From a National Cohort Study. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2020, 84: 26-36. PMID: 32267658, PMCID: PMC7147724, DOI: 10.1097/qai.0000000000002310.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCohort StudiesFemaleHIV InfectionsHumansMaleMiddle AgedOpioid-Related DisordersUnited StatesConceptsOpioid useOpioid use trajectoriesCohort studyPain interferenceSelf-reported opioid useVeterans Aging Cohort StudyVeterans Health Administration sitesInfrequent useOpioid use frequencyMarijuana useAging Cohort StudyNational cohort studyEvidence-based treatmentsGroup-based trajectory modelsProspective cohortBaseline factorsIllness severityMultivariable analysisBenzodiazepine medicationVA carePsychoactive medicationsPrescription painkillersPsychiatric symptomsHeroin useMultinomial logistic regression
2019
Predictors of timely opioid agonist treatment initiation among veterans with and without HIV
Wyse JJ, Robbins JL, McGinnis KA, Edelman EJ, Gordon AJ, Manhapra A, Fiellin DA, Moore BA, Korthuis PT, Gaither JR, Gordon K, Skanderson M, Barry DT, Crystal S, Justice A, Kraemer KL. Predictors of timely opioid agonist treatment initiation among veterans with and without HIV. Drug And Alcohol Dependence 2019, 198: 70-75. PMID: 30878769, PMCID: PMC6836871, DOI: 10.1016/j.drugalcdep.2019.01.038.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyOpioid use disorderVeterans Aging Cohort StudyOAT initiationUninfected patientsClinical encountersNational observational cohortAging Cohort StudyAfrican American patientsImproved health outcomesAgonist therapyCohort studyObservational cohortTreatment initiationPredictive factorsEffective treatmentAdjusted modelUninfected controlsUse disordersPsychiatric diagnosisPWHClinical practicePatientsHealth outcomesRural residence
2018
Efficacy of Extended-Release Naltrexone on HIV-Related and Drinking Outcomes Among HIV-Positive Patients: A Randomized-Controlled Trial
Edelman EJ, Moore BA, Holt SR, Hansen N, Kyriakides TC, Virata M, Brown ST, Justice AC, Bryant KJ, Fiellin DA, Fiellin LE. Efficacy of Extended-Release Naltrexone on HIV-Related and Drinking Outcomes Among HIV-Positive Patients: A Randomized-Controlled Trial. AIDS And Behavior 2018, 23: 211-221. PMID: 30073637, PMCID: PMC6476298, DOI: 10.1007/s10461-018-2241-z.Peer-Reviewed Original ResearchConceptsHIV-positive patientsHeavy drinking daysVACS Index scoreXR-NTXART adherenceDrinking daysIndex scoreUndetectable HIV viral loadCD4 cell countExtended-release naltrexoneDouble-blind placeboHIV viral loadRandomized-controlled trialDrinking outcomesHIV biomarkersSecondary outcomesHIV outcomesPrimary outcomeViral loadAntiretroviral adherenceClinical trialsCell countAlcohol treatmentHIVPatients
2016
Primary Care Physicians’ Willingness to Prescribe HIV Pre-exposure Prophylaxis for People who Inject Drugs
Edelman EJ, Moore BA, Calabrese SK, Berkenblit G, Cunningham C, Patel V, Phillips K, Tetrault JM, Shah M, Fiellin DA, Blackstock O. Primary Care Physicians’ Willingness to Prescribe HIV Pre-exposure Prophylaxis for People who Inject Drugs. AIDS And Behavior 2016, 21: 1025-1033. PMID: 27896552, PMCID: PMC5344709, DOI: 10.1007/s10461-016-1612-6.Peer-Reviewed Original ResearchConceptsPrimary care physiciansPre-exposure prophylaxisCare physiciansHIV pre-exposure prophylaxisHIV risk groupMore HIVClinic patientsRisk groupsGeneral internistsPWIDAcademic general internistsPractice characteristicsDisease preventionHIVPrEPProphylaxisPatientsPhysiciansCareDrugsOnline surveyInternistsHigher willingnessLower willingnessCentral roleA Cross-Sectional Online Survey of HIV Pre-Exposure Prophylaxis Adoption Among Primary Care Physicians
Blackstock OJ, Moore BA, Berkenblit GV, Calabrese SK, Cunningham CO, Fiellin DA, Patel VV, Phillips KA, Tetrault JM, Shah M, Edelman EJ. A Cross-Sectional Online Survey of HIV Pre-Exposure Prophylaxis Adoption Among Primary Care Physicians. Journal Of General Internal Medicine 2016, 32: 62-70. PMID: 27778215, PMCID: PMC5215171, DOI: 10.1007/s11606-016-3903-z.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-HIV AgentsCross-Sectional StudiesFemaleHealth Knowledge, Attitudes, PracticeHealth PersonnelHealth Risk BehaviorsHIV InfectionsHumansMaleMiddle AgedMultivariate AnalysisOdds RatioPractice Patterns, Physicians'Pre-Exposure ProphylaxisPrimary Health CareSurveys and QuestionnairesConceptsPrimary care physiciansHIV care experienceCare physiciansPrEP adoptionPrEP awarenessPractice characteristicsHIV pre-exposure prophylaxisCare experiencesAcademic primary care physiciansHIV-positive patientsPre-exposure prophylaxisHealth care providersResultsThe survey response rateSectional Online SurveyPCP adoptionHIV careKey ResultsThe survey response ratePercent of respondentsRisk compensationSurvey response ratePrEP knowledgePrEP useSelf-rated knowledgeMultivariable analysisClinical champions
2015
Long-term Prescription of Opioids and/or Benzodiazepines and Mortality Among HIV-Infected and Uninfected Patients
Weisberg DF, Gordon KS, Barry DT, Becker WC, Crystal S, Edelman EJ, Gaither J, Gordon AJ, Goulet J, Kerns RD, Moore BA, Tate J, Justice AC, Fiellin DA. Long-term Prescription of Opioids and/or Benzodiazepines and Mortality Among HIV-Infected and Uninfected Patients. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2015, 69: 223-233. PMID: 26009831, PMCID: PMC4446730, DOI: 10.1097/qai.0000000000000591.Peer-Reviewed Original ResearchConceptsLong-term opioidsMorphine equivalent daily doseOpioid receiptRisk of deathLong-term prescriptionUninfected patientsOpioid dosesAntiretroviral therapyHazard ratioDaily dosePropensity scoreHigher opioid dosesCause mortalityHIV statusAvailable patientsMortality riskOpioidsHIVPatientsProspective analysisMortalityBenzodiazepinesDosesDeathRiskA Remotely-Delivered CBT and Contingency Management Therapy for Substance Using People with HIV
Moore BA, Rosen MI, Wang Y, Shen J, Ablondi K, Sullivan A, Guerrero M, Siqueiros L, Daar ES, Liu H. A Remotely-Delivered CBT and Contingency Management Therapy for Substance Using People with HIV. AIDS And Behavior 2015, 19: 156-162. PMID: 25645326, PMCID: PMC4498993, DOI: 10.1007/s10461-014-0990-x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Retroviral AgentsCaliforniaCognitive Behavioral TherapyDirective CounselingFeasibility StudiesFemaleHIV InfectionsHumansMaleMedication AdherenceMotivationPatient Acceptance of Health CareProgram EvaluationSubstance Abuse, IntravenousSubstance-Related DisordersTelephoneTreatment OutcomeYoung AdultConceptsAntiretroviral therapyContingency managementContingency management therapyBehavior therapy sessionsHIV patientsMedication adherenceTelephone sessionsPrescribed dosesParticipant adherenceManagement therapyPrior interventionsPromising interventionAlcohol useAdherenceTherapy sessionsHIVPatientsTherapyModest effectCognitive behavior therapy sessionsWeeksInterventionSessionsDosesCare
2013
HIV Testing and Sexual Risk Reduction Counseling in Office-Based Buprenorphine/Naloxone Treatment
Edelman EJ, Moore BA, Caffrey S, Sikkema KJ, Jones ES, Schottenfeld RS, Fiellin DA, Fiellin LE. HIV Testing and Sexual Risk Reduction Counseling in Office-Based Buprenorphine/Naloxone Treatment. Journal Of Addiction Medicine 2013, 7: 410-416. PMID: 24189173, DOI: 10.1097/adm.0b013e3182a3b603.Peer-Reviewed Original ResearchConceptsSexual risk reduction counselingRisk reduction counselingBuprenorphine/naloxone treatmentOpioid-dependent patientsReduction counselingSexual risk behaviorsHIV testingNaloxone treatmentHuman immunodeficiency virus (HIV) testingRisk behaviorsPreliminary efficacyVirus testingPatientsManual adherenceTreatment practicesProcess measuresCounseling sessionsSimilar proportionsHIVCounselingOutcomesTreatmentSessionsRandomizedTesting
2012
Brief versus extended counseling along with buprenorphine/naloxone for HIV-infected opioid dependent patients
Tetrault JM, Moore BA, Barry DT, O'Connor PG, Schottenfeld R, Fiellin DA, Fiellin LE. Brief versus extended counseling along with buprenorphine/naloxone for HIV-infected opioid dependent patients. Journal Of Substance Use And Addiction Treatment 2012, 43: 433-439. PMID: 22938914, DOI: 10.1016/j.jsat.2012.07.011.Peer-Reviewed Original ResearchMeSH KeywordsAdultBuprenorphineBuprenorphine, Naloxone Drug CombinationCounselingDelivery of Health Care, IntegratedFeasibility StudiesFemaleFollow-Up StudiesHIV InfectionsHumansMaleMiddle AgedNaloxoneNarcotic AntagonistsOpioid-Related DisordersPsychotherapy, BriefSubstance Abuse DetectionTime FactorsTreatment OutcomeViral LoadConceptsEnhanced medical managementPhysician managementDetectable HIV viral loadHIV treatment settingsOpioid-negative urinesBuprenorphine/naloxoneHIV viral loadOpioid-dependent patientsPercentage of subjectsUntreated opioid dependenceExtended counselingHIV clinicHIV outcomesBuprenorphine/Medical managementOpioid dependenceViral loadDependent patientsExtensive counselingClinical trialsContinuous abstinenceNegative urineTreatment settingsGroup differencesCounseling
2006
A Trial of Integrated Buprenorphine/Naloxone and HIV Clinical Care
Sullivan LE, Barry D, Moore BA, Chawarski MC, Tetrault JM, Pantalon MV, O'Connor PG, Schottenfeld RS, Fiellin DA. A Trial of Integrated Buprenorphine/Naloxone and HIV Clinical Care. Clinical Infectious Diseases 2006, 43: s184-s190. PMID: 17109305, DOI: 10.1086/508182.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, SublingualAdultAntiretroviral Therapy, Highly ActiveBuprenorphineDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHIV InfectionsHumansMaleMiddle AgedNaloxoneNarcotic AntagonistsOpioid-Related DisordersPilot ProjectsProbabilityReference ValuesRisk FactorsTreatment OutcomeConceptsHIV clinical careHIV-1 RNA copies/mLBuprenorphine/naloxone treatmentRNA copies/mLCopies/mLOpioid dependenceClinical careOpioid useNaloxone treatmentPhysician managementTreatment retentionHIV type 1 RNA levelsHIV-1 RNA levelsDose of buprenorphinePartial opioid agonistRNA levelsCD4 lymphocyte countBuprenorphine/naloxoneOpioid-dependent patientsUrine toxicology testsWeeks of treatmentHuman immunodeficiency virusUrine test resultsBetter treatment retentionUntreated opioid dependence
2005
Response to hepatitis A vaccine in HIV‐positive patients1
Weissman S, Feucht C, Moore BA. Response to hepatitis A vaccine in HIV‐positive patients1. Journal Of Viral Hepatitis 2005, 13: 81-86. PMID: 16436125, DOI: 10.1111/j.1365-2893.2005.00658.x.Peer-Reviewed Original ResearchConceptsHepatitis A virusHigher CD4 countsHuman immunodeficiency virusCD4 countHAV vaccineVaccine administrationFemale genderImmune responseMultivariate analysisHepatitis C virus exposureUSPHS/IDSA guidelinesHIV-negative patientsAntiretroviral therapy useChronic liver diseasePredictors of responseLow viral loadIDSA guidelinesVaccination seriesHIV patientsIndependent predictorsTherapy useLiver diseaseOpportunistic infectionsViral loadImmunodeficiency virus
1998
Community Reinforcement Approach in the Treatment of Opiate Addicts
Abbott P, Weller S, Delaney H, Moore B. Community Reinforcement Approach in the Treatment of Opiate Addicts. The American Journal Of Drug And Alcohol Abuse 1998, 24: 17-30. PMID: 9513627, DOI: 10.3109/00952999809001696.Peer-Reviewed Original ResearchConceptsCommunity Reinforcement ApproachMethadone maintenanceCRA groupASI drug composite scoresSeverity Index scoreTreatment of patientsOpiate-dependent patientsAddiction Severity Index (ASI) scoresDrug composite scoresStandard counselingTreatment exposureReinforcement approachIndex scoreRelapse preventionStandard groupDrug screensOpiate addictsRP sessionsComposite scorePatientsAdditive effectIntakeMonthsTreatmentScores